| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 42 | 2025 | 645 | 5.310 |
Why?
|
| Sleep Apnea, Obstructive | 20 | 2025 | 239 | 5.210 |
Why?
|
| Sleep Apnea Syndromes | 12 | 2026 | 91 | 4.310 |
Why?
|
| Polysomnography | 19 | 2026 | 155 | 3.520 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 8 | 2026 | 100 | 3.310 |
Why?
|
| Veterans | 23 | 2026 | 1752 | 3.210 |
Why?
|
| Disorders of Excessive Somnolence | 6 | 2025 | 44 | 2.860 |
Why?
|
| Sleep Wake Disorders | 7 | 2026 | 202 | 2.790 |
Why?
|
| Sleep | 16 | 2026 | 369 | 2.530 |
Why?
|
| Sleep Medicine Specialty | 2 | 2026 | 12 | 1.890 |
Why?
|
| Bronchodilator Agents | 14 | 2018 | 156 | 1.730 |
Why?
|
| Artificial Intelligence | 3 | 2026 | 348 | 1.500 |
Why?
|
| Sleep Stages | 5 | 2026 | 30 | 1.430 |
Why?
|
| Comorbidity | 14 | 2026 | 1583 | 1.370 |
Why?
|
| Pneumonia | 5 | 2024 | 340 | 1.160 |
Why?
|
| Telemedicine | 4 | 2025 | 525 | 1.160 |
Why?
|
| Pulmonary Emphysema | 6 | 2014 | 96 | 1.110 |
Why?
|
| Humans | 124 | 2026 | 130154 | 1.040 |
Why?
|
| Middle Aged | 58 | 2026 | 28331 | 1.020 |
Why?
|
| Continuous Positive Airway Pressure | 6 | 2020 | 62 | 0.990 |
Why?
|
| Narcolepsy | 1 | 2026 | 8 | 0.960 |
Why?
|
| Smoke Inhalation Injury | 1 | 2025 | 8 | 0.940 |
Why?
|
| Sleep Hygiene | 1 | 2025 | 10 | 0.930 |
Why?
|
| Specialty Boards | 1 | 2025 | 21 | 0.910 |
Why?
|
| Asthma | 7 | 2026 | 921 | 0.910 |
Why?
|
| Mortality | 3 | 2025 | 261 | 0.890 |
Why?
|
| Aged | 48 | 2026 | 20833 | 0.870 |
Why?
|
| Machine Learning | 3 | 2026 | 380 | 0.840 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 3 | 2014 | 50 | 0.820 |
Why?
|
| United States Department of Veterans Affairs | 5 | 2026 | 711 | 0.810 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2025 | 141 | 0.800 |
Why?
|
| Respiratory Mechanics | 3 | 2017 | 80 | 0.800 |
Why?
|
| Retrospective Studies | 24 | 2026 | 17554 | 0.800 |
Why?
|
| Clinical Decision-Making | 1 | 2025 | 309 | 0.760 |
Why?
|
| Male | 65 | 2026 | 64397 | 0.750 |
Why?
|
| Ethanolamines | 3 | 2011 | 24 | 0.750 |
Why?
|
| United States | 24 | 2026 | 11885 | 0.710 |
Why?
|
| Quality of Life | 17 | 2025 | 2072 | 0.710 |
Why?
|
| Forced Expiratory Volume | 15 | 2017 | 178 | 0.710 |
Why?
|
| Nebulizers and Vaporizers | 5 | 2018 | 60 | 0.700 |
Why?
|
| Female | 61 | 2026 | 70285 | 0.690 |
Why?
|
| Respiratory Function Tests | 7 | 2013 | 222 | 0.690 |
Why?
|
| Primary Health Care | 2 | 2026 | 768 | 0.680 |
Why?
|
| Hypoxia | 4 | 2023 | 247 | 0.680 |
Why?
|
| Budesonide | 2 | 2011 | 18 | 0.680 |
Why?
|
| Patient Care Team | 1 | 2025 | 558 | 0.670 |
Why?
|
| Electroencephalography | 5 | 2026 | 849 | 0.650 |
Why?
|
| Albuterol | 6 | 2014 | 53 | 0.640 |
Why?
|
| Elective Surgical Procedures | 1 | 2021 | 161 | 0.620 |
Why?
|
| REM Sleep Behavior Disorder | 3 | 2025 | 19 | 0.610 |
Why?
|
| Cohort Studies | 10 | 2026 | 5042 | 0.580 |
Why?
|
| Myocardial Infarction | 2 | 2023 | 996 | 0.580 |
Why?
|
| Patient Readmission | 2 | 2024 | 435 | 0.570 |
Why?
|
| Smoking | 9 | 2022 | 927 | 0.570 |
Why?
|
| Pneumonectomy | 4 | 2008 | 154 | 0.560 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2026 | 331 | 0.560 |
Why?
|
| Adult | 29 | 2026 | 31042 | 0.550 |
Why?
|
| Wearable Electronic Devices | 5 | 2026 | 121 | 0.540 |
Why?
|
| Self Report | 3 | 2025 | 550 | 0.530 |
Why?
|
| Severity of Illness Index | 15 | 2025 | 3025 | 0.530 |
Why?
|
| Oxygen Inhalation Therapy | 2 | 2008 | 88 | 0.510 |
Why?
|
| Betacoronavirus | 1 | 2020 | 273 | 0.510 |
Why?
|
| Hospitalization | 6 | 2022 | 1934 | 0.490 |
Why?
|
| Diaphragm | 1 | 2017 | 100 | 0.490 |
Why?
|
| Case-Control Studies | 6 | 2022 | 3350 | 0.480 |
Why?
|
| Iran | 3 | 2025 | 93 | 0.480 |
Why?
|
| No-Show Patients | 1 | 2016 | 2 | 0.480 |
Why?
|
| Dyspnea | 3 | 2016 | 159 | 0.480 |
Why?
|
| Obesity | 3 | 2023 | 2394 | 0.470 |
Why?
|
| Respiratory System Agents | 1 | 2015 | 3 | 0.460 |
Why?
|
| Respiratory Therapy | 1 | 2015 | 19 | 0.460 |
Why?
|
| Frailty | 4 | 2021 | 140 | 0.460 |
Why?
|
| Respiration Disorders | 1 | 2015 | 30 | 0.450 |
Why?
|
| Risk Factors | 16 | 2025 | 10953 | 0.450 |
Why?
|
| Phenotype | 2 | 2024 | 4464 | 0.440 |
Why?
|
| Lung Transplantation | 1 | 2019 | 352 | 0.440 |
Why?
|
| Disease Progression | 6 | 2017 | 2193 | 0.430 |
Why?
|
| Heart Diseases | 2 | 2017 | 500 | 0.420 |
Why?
|
| Lung | 4 | 2017 | 1533 | 0.420 |
Why?
|
| Troponin T | 1 | 2015 | 255 | 0.410 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 231 | 0.410 |
Why?
|
| Colonoscopy | 1 | 2016 | 241 | 0.400 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2025 | 639 | 0.400 |
Why?
|
| Metered Dose Inhalers | 4 | 2014 | 12 | 0.380 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2022 | 510 | 0.350 |
Why?
|
| Ambulatory Care | 1 | 2014 | 401 | 0.340 |
Why?
|
| Brain | 4 | 2026 | 3146 | 0.340 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 1448 | 0.340 |
Why?
|
| Patient Preference | 1 | 2013 | 151 | 0.340 |
Why?
|
| Wavelet Analysis | 1 | 2011 | 7 | 0.340 |
Why?
|
| Impotence, Vasculogenic | 1 | 2011 | 6 | 0.340 |
Why?
|
| Myocardium | 1 | 2015 | 858 | 0.320 |
Why?
|
| Positive-Pressure Respiration | 2 | 2014 | 83 | 0.320 |
Why?
|
| Administration, Inhalation | 5 | 2018 | 192 | 0.320 |
Why?
|
| Vital Capacity | 5 | 2017 | 81 | 0.320 |
Why?
|
| Surveys and Questionnaires | 13 | 2025 | 4032 | 0.310 |
Why?
|
| Cross-Sectional Studies | 9 | 2024 | 3781 | 0.310 |
Why?
|
| Scopolamine Derivatives | 4 | 2011 | 11 | 0.290 |
Why?
|
| International Classification of Diseases | 3 | 2024 | 92 | 0.290 |
Why?
|
| Age Factors | 7 | 2025 | 2823 | 0.290 |
Why?
|
| Treatment Outcome | 16 | 2025 | 12843 | 0.290 |
Why?
|
| Time Factors | 7 | 2022 | 6178 | 0.290 |
Why?
|
| Frail Elderly | 5 | 2021 | 107 | 0.290 |
Why?
|
| Cost of Illness | 2 | 2010 | 293 | 0.280 |
Why?
|
| Delivery of Health Care | 2 | 2016 | 683 | 0.280 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 698 | 0.280 |
Why?
|
| Longitudinal Studies | 6 | 2024 | 1485 | 0.270 |
Why?
|
| Cardiac Pacing, Artificial | 3 | 2006 | 133 | 0.270 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2007 | 27 | 0.270 |
Why?
|
| Endopeptidases | 1 | 2008 | 106 | 0.270 |
Why?
|
| Propensity Score | 2 | 2026 | 273 | 0.270 |
Why?
|
| Geriatric Assessment | 4 | 2021 | 183 | 0.270 |
Why?
|
| Phytotherapy | 1 | 2007 | 47 | 0.260 |
Why?
|
| Logistic Models | 7 | 2025 | 1793 | 0.260 |
Why?
|
| Pulmonary Alveoli | 1 | 2008 | 140 | 0.260 |
Why?
|
| Heart Failure | 3 | 2023 | 2322 | 0.260 |
Why?
|
| Body Weight | 1 | 2011 | 985 | 0.250 |
Why?
|
| Prevalence | 10 | 2024 | 2685 | 0.250 |
Why?
|
| Caregivers | 1 | 2013 | 583 | 0.250 |
Why?
|
| Neuronal Plasticity | 2 | 2026 | 285 | 0.250 |
Why?
|
| Intraoperative Complications | 1 | 2008 | 154 | 0.250 |
Why?
|
| Bronchoscopy | 2 | 2008 | 178 | 0.250 |
Why?
|
| Telerehabilitation | 2 | 2025 | 10 | 0.250 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 908 | 0.240 |
Why?
|
| Memory Consolidation | 1 | 2026 | 10 | 0.240 |
Why?
|
| Limbic System | 1 | 2026 | 23 | 0.240 |
Why?
|
| United States Department of Defense | 1 | 2026 | 11 | 0.240 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2012 | 298 | 0.240 |
Why?
|
| Hypercapnia | 1 | 2026 | 22 | 0.240 |
Why?
|
| Insulin Resistance | 1 | 2011 | 685 | 0.240 |
Why?
|
| Brain Waves | 1 | 2026 | 42 | 0.240 |
Why?
|
| Body Mass Index | 3 | 2023 | 1685 | 0.240 |
Why?
|
| Databases, Factual | 4 | 2025 | 1230 | 0.230 |
Why?
|
| Dreams | 1 | 2025 | 23 | 0.230 |
Why?
|
| Executive Function | 1 | 2026 | 122 | 0.230 |
Why?
|
| Anxiety Disorders | 3 | 2007 | 726 | 0.230 |
Why?
|
| Aging | 2 | 2010 | 1236 | 0.220 |
Why?
|
| Electronic Health Records | 2 | 2025 | 831 | 0.220 |
Why?
|
| Heart Atria | 3 | 2006 | 339 | 0.220 |
Why?
|
| Attention | 1 | 2026 | 191 | 0.220 |
Why?
|
| Carbon Dioxide | 1 | 2026 | 269 | 0.220 |
Why?
|
| Feasibility Studies | 2 | 2025 | 814 | 0.220 |
Why?
|
| Unsupervised Machine Learning | 1 | 2024 | 12 | 0.210 |
Why?
|
| Aftercare | 2 | 2024 | 150 | 0.210 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2026 | 133 | 0.210 |
Why?
|
| Psychotic Disorders | 1 | 2005 | 146 | 0.210 |
Why?
|
| Mediastinal Diseases | 1 | 2003 | 14 | 0.200 |
Why?
|
| Functional Residual Capacity | 2 | 2017 | 15 | 0.200 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2024 | 119 | 0.200 |
Why?
|
| Emotions | 1 | 2026 | 349 | 0.200 |
Why?
|
| Nerve Net | 1 | 2026 | 254 | 0.200 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2026 | 246 | 0.200 |
Why?
|
| Self-Assessment | 1 | 2003 | 57 | 0.200 |
Why?
|
| Military Personnel | 1 | 2026 | 216 | 0.190 |
Why?
|
| Cerebral Cortex | 1 | 2026 | 447 | 0.190 |
Why?
|
| Biomarkers | 7 | 2023 | 3360 | 0.190 |
Why?
|
| Sleep Apnea, Central | 1 | 2023 | 10 | 0.190 |
Why?
|
| Cluster Analysis | 1 | 2024 | 412 | 0.190 |
Why?
|
| Cognition | 2 | 2026 | 817 | 0.190 |
Why?
|
| Texas | 4 | 2017 | 3648 | 0.190 |
Why?
|
| Formoterol Fumarate | 3 | 2011 | 29 | 0.190 |
Why?
|
| Bipolar Disorder | 1 | 2005 | 344 | 0.180 |
Why?
|
| Aged, 80 and over | 7 | 2023 | 6768 | 0.180 |
Why?
|
| Cardiac Rehabilitation | 1 | 2022 | 29 | 0.180 |
Why?
|
| Health Surveys | 1 | 2003 | 256 | 0.180 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2024 | 164 | 0.180 |
Why?
|
| Blood Pressure | 2 | 2006 | 1340 | 0.180 |
Why?
|
| Apoptosis | 1 | 2008 | 1830 | 0.170 |
Why?
|
| Patient Discharge | 2 | 2024 | 512 | 0.170 |
Why?
|
| Remote Sensing Technology | 1 | 2021 | 4 | 0.170 |
Why?
|
| Signal Transduction | 4 | 2026 | 4656 | 0.170 |
Why?
|
| Multivariate Analysis | 5 | 2016 | 1374 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 2058 | 0.170 |
Why?
|
| RNA, Long Noncoding | 1 | 2023 | 219 | 0.170 |
Why?
|
| Social Media | 1 | 2022 | 120 | 0.160 |
Why?
|
| Ipratropium | 2 | 2011 | 8 | 0.160 |
Why?
|
| Proportional Hazards Models | 5 | 2016 | 1392 | 0.160 |
Why?
|
| Cause of Death | 4 | 2025 | 500 | 0.160 |
Why?
|
| Lung Diseases | 1 | 2024 | 397 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2014 | 1606 | 0.160 |
Why?
|
| Accelerometry | 1 | 2020 | 67 | 0.160 |
Why?
|
| Physical Examination | 1 | 2021 | 166 | 0.160 |
Why?
|
| Respiratory Tract Diseases | 2 | 2014 | 81 | 0.150 |
Why?
|
| Humidity | 1 | 2019 | 26 | 0.150 |
Why?
|
| Chronic Disease | 1 | 2024 | 1241 | 0.150 |
Why?
|
| Outpatients | 1 | 2021 | 263 | 0.150 |
Why?
|
| Total Lung Capacity | 2 | 2017 | 11 | 0.150 |
Why?
|
| Occupational Health | 1 | 2019 | 43 | 0.150 |
Why?
|
| Algorithms | 2 | 2024 | 1661 | 0.150 |
Why?
|
| Bronchi | 2 | 2012 | 98 | 0.150 |
Why?
|
| Veterans Health | 1 | 2021 | 170 | 0.150 |
Why?
|
| Hospital Mortality | 2 | 2022 | 1057 | 0.150 |
Why?
|
| HIV Infections | 3 | 2018 | 2040 | 0.150 |
Why?
|
| Workplace | 1 | 2019 | 80 | 0.140 |
Why?
|
| Hydrocortisone | 1 | 2019 | 213 | 0.140 |
Why?
|
| Musculoskeletal Diseases | 1 | 2019 | 56 | 0.140 |
Why?
|
| Job Satisfaction | 1 | 2019 | 99 | 0.140 |
Why?
|
| Fatigue | 2 | 2012 | 191 | 0.140 |
Why?
|
| Data Accuracy | 1 | 2018 | 28 | 0.140 |
Why?
|
| Animals | 15 | 2026 | 33698 | 0.140 |
Why?
|
| Nurses | 1 | 2019 | 64 | 0.140 |
Why?
|
| Interleukin-4 | 1 | 2018 | 145 | 0.130 |
Why?
|
| Interleukin-13 | 1 | 2018 | 98 | 0.130 |
Why?
|
| Workload | 1 | 2019 | 149 | 0.130 |
Why?
|
| Iowa | 1 | 2017 | 13 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2026 | 3744 | 0.130 |
Why?
|
| Actigraphy | 1 | 2017 | 53 | 0.130 |
Why?
|
| Acute Disease | 3 | 2016 | 1157 | 0.130 |
Why?
|
| Models, Biological | 2 | 2017 | 1376 | 0.130 |
Why?
|
| Motor Activity | 1 | 2020 | 488 | 0.130 |
Why?
|
| Pandemics | 2 | 2022 | 1114 | 0.120 |
Why?
|
| Sensitivity and Specificity | 4 | 2017 | 2079 | 0.120 |
Why?
|
| Patient Education as Topic | 2 | 2012 | 460 | 0.120 |
Why?
|
| Symptom Flare Up | 1 | 2016 | 25 | 0.120 |
Why?
|
| Cough | 2 | 2016 | 98 | 0.120 |
Why?
|
| Electrooculography | 2 | 2006 | 6 | 0.120 |
Why?
|
| Adrenergic beta-Agonists | 3 | 2008 | 79 | 0.120 |
Why?
|
| Protective Factors | 1 | 2016 | 90 | 0.120 |
Why?
|
| Bronchitis, Chronic | 1 | 2016 | 16 | 0.120 |
Why?
|
| Pulmonary Diffusing Capacity | 2 | 2013 | 8 | 0.120 |
Why?
|
| Hospitals, District | 1 | 2016 | 6 | 0.120 |
Why?
|
| Patient Admission | 1 | 2017 | 184 | 0.120 |
Why?
|
| Appointments and Schedules | 1 | 2016 | 48 | 0.120 |
Why?
|
| Postoperative Complications | 1 | 2008 | 3113 | 0.120 |
Why?
|
| Sleep Deprivation | 2 | 2026 | 44 | 0.120 |
Why?
|
| Linear Models | 3 | 2016 | 684 | 0.120 |
Why?
|
| Electromyography | 2 | 2006 | 135 | 0.110 |
Why?
|
| Health Status | 3 | 2013 | 371 | 0.110 |
Why?
|
| Depressive Disorder | 2 | 2010 | 460 | 0.110 |
Why?
|
| Aerosols | 1 | 2015 | 57 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 338 | 0.110 |
Why?
|
| Drug Administration Schedule | 2 | 2014 | 724 | 0.110 |
Why?
|
| Reminder Systems | 1 | 2016 | 61 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 349 | 0.110 |
Why?
|
| Reproducibility of Results | 4 | 2024 | 2896 | 0.110 |
Why?
|
| Costs and Cost Analysis | 1 | 2016 | 151 | 0.110 |
Why?
|
| Particle Size | 1 | 2015 | 135 | 0.110 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2014 | 55 | 0.110 |
Why?
|
| CD4 Antigens | 1 | 2014 | 53 | 0.110 |
Why?
|
| Survival Rate | 2 | 2017 | 2112 | 0.110 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 2094 | 0.110 |
Why?
|
| Health Resources | 1 | 2016 | 129 | 0.110 |
Why?
|
| Double-Blind Method | 4 | 2011 | 1618 | 0.110 |
Why?
|
| Testosterone | 1 | 2019 | 528 | 0.100 |
Why?
|
| Drug Delivery Systems | 1 | 2015 | 217 | 0.100 |
Why?
|
| Antipsychotic Agents | 1 | 2017 | 371 | 0.100 |
Why?
|
| Patient Satisfaction | 2 | 2014 | 461 | 0.100 |
Why?
|
| Program Development | 1 | 2014 | 181 | 0.100 |
Why?
|
| Equipment Design | 1 | 2015 | 510 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 1070 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2015 | 647 | 0.100 |
Why?
|
| Dry Powder Inhalers | 1 | 2013 | 4 | 0.100 |
Why?
|
| Physical Exertion | 1 | 2013 | 63 | 0.100 |
Why?
|
| Program Evaluation | 1 | 2014 | 444 | 0.090 |
Why?
|
| Heart Rate | 3 | 2006 | 573 | 0.090 |
Why?
|
| Hypertension, Pulmonary | 1 | 2017 | 455 | 0.090 |
Why?
|
| Case Management | 1 | 2012 | 17 | 0.090 |
Why?
|
| Respiratory Mucosa | 1 | 2012 | 93 | 0.090 |
Why?
|
| Intensive Care Units | 1 | 2016 | 525 | 0.090 |
Why?
|
| Spirometry | 4 | 2018 | 92 | 0.090 |
Why?
|
| Risk Assessment | 3 | 2014 | 3680 | 0.090 |
Why?
|
| Thorax | 2 | 2017 | 62 | 0.090 |
Why?
|
| Perception | 1 | 2013 | 228 | 0.090 |
Why?
|
| Resistin | 1 | 2011 | 30 | 0.090 |
Why?
|
| Emphysema | 1 | 2012 | 67 | 0.080 |
Why?
|
| Ghrelin | 1 | 2011 | 57 | 0.080 |
Why?
|
| Appetite Regulation | 1 | 2011 | 39 | 0.080 |
Why?
|
| Exhalation | 1 | 2011 | 16 | 0.080 |
Why?
|
| Budesonide, Formoterol Fumarate Drug Combination | 1 | 2010 | 3 | 0.080 |
Why?
|
| Adiponectin | 1 | 2011 | 122 | 0.080 |
Why?
|
| Health Care Costs | 1 | 2014 | 406 | 0.080 |
Why?
|
| Penile Erection | 1 | 2011 | 72 | 0.080 |
Why?
|
| Breath Tests | 1 | 2011 | 182 | 0.080 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2012 | 292 | 0.080 |
Why?
|
| Observation | 1 | 2010 | 40 | 0.080 |
Why?
|
| Clinical Trials as Topic | 3 | 2015 | 1121 | 0.080 |
Why?
|
| Laryngismus | 1 | 2009 | 4 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 563 | 0.080 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2009 | 22 | 0.080 |
Why?
|
| Drug Therapy | 1 | 2010 | 85 | 0.080 |
Why?
|
| Pulmonary Medicine | 1 | 2010 | 33 | 0.080 |
Why?
|
| Drug Combinations | 1 | 2010 | 268 | 0.080 |
Why?
|
| Restless Legs Syndrome | 1 | 2009 | 16 | 0.080 |
Why?
|
| Anti-Dyskinesia Agents | 1 | 2009 | 40 | 0.080 |
Why?
|
| Mucus | 2 | 2007 | 37 | 0.080 |
Why?
|
| Tiotropium Bromide | 4 | 2011 | 14 | 0.070 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2009 | 67 | 0.070 |
Why?
|
| Observer Variation | 2 | 2012 | 311 | 0.070 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 355 | 0.070 |
Why?
|
| Follow-Up Studies | 5 | 2014 | 5161 | 0.070 |
Why?
|
| Residual Volume | 1 | 2008 | 2 | 0.070 |
Why?
|
| Psychometrics | 1 | 2012 | 675 | 0.070 |
Why?
|
| Respiratory Muscles | 1 | 2008 | 7 | 0.070 |
Why?
|
| Aircraft | 1 | 2008 | 19 | 0.070 |
Why?
|
| Botulinum Toxins | 1 | 2009 | 112 | 0.070 |
Why?
|
| Justicia | 1 | 2007 | 3 | 0.070 |
Why?
|
| Tylophora | 1 | 2007 | 3 | 0.070 |
Why?
|
| Picrorhiza | 1 | 2007 | 3 | 0.070 |
Why?
|
| Ambroxol | 1 | 2007 | 5 | 0.070 |
Why?
|
| Expectorants | 1 | 2007 | 8 | 0.070 |
Why?
|
| Pulmonary Surfactants | 1 | 2008 | 45 | 0.070 |
Why?
|
| Prostaglandins | 1 | 2007 | 35 | 0.070 |
Why?
|
| Age Distribution | 2 | 2010 | 421 | 0.070 |
Why?
|
| Nitric Oxide | 1 | 2011 | 466 | 0.070 |
Why?
|
| Prospective Studies | 4 | 2010 | 6403 | 0.070 |
Why?
|
| Stilbenes | 1 | 2007 | 34 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2025 | 1208 | 0.070 |
Why?
|
| Cholinergic Antagonists | 1 | 2008 | 46 | 0.070 |
Why?
|
| Curcumin | 1 | 2007 | 40 | 0.070 |
Why?
|
| Incidence | 3 | 2017 | 3314 | 0.060 |
Why?
|
| Atrial Fibrillation | 3 | 2000 | 734 | 0.060 |
Why?
|
| Life Expectancy | 1 | 2007 | 63 | 0.060 |
Why?
|
| Plethysmography | 1 | 2006 | 34 | 0.060 |
Why?
|
| Blood Glucose | 1 | 2011 | 1108 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 641 | 0.060 |
Why?
|
| Isoproterenol | 1 | 2006 | 85 | 0.060 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2007 | 141 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2024 | 2289 | 0.060 |
Why?
|
| Insulin | 1 | 2011 | 1143 | 0.060 |
Why?
|
| Activities of Daily Living | 2 | 2022 | 388 | 0.060 |
Why?
|
| Nocturnal Myoclonus Syndrome | 1 | 2005 | 1 | 0.060 |
Why?
|
| Prosthesis Failure | 1 | 2006 | 159 | 0.060 |
Why?
|
| Hemodynamics | 2 | 2008 | 810 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2007 | 290 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2008 | 460 | 0.060 |
Why?
|
| Plethysmography, Whole Body | 1 | 2005 | 2 | 0.060 |
Why?
|
| Respiratory System | 1 | 2006 | 95 | 0.060 |
Why?
|
| Cystic Fibrosis | 1 | 2007 | 267 | 0.050 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2005 | 31 | 0.050 |
Why?
|
| Demography | 1 | 2005 | 237 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 2 | 2018 | 225 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2007 | 410 | 0.050 |
Why?
|
| Noise | 1 | 2004 | 17 | 0.050 |
Why?
|
| ROC Curve | 2 | 2021 | 609 | 0.050 |
Why?
|
| Prefrontal Cortex | 1 | 2026 | 208 | 0.050 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2003 | 9 | 0.050 |
Why?
|
| Memory Disorders | 1 | 2005 | 190 | 0.050 |
Why?
|
| Autophagy | 1 | 2007 | 419 | 0.050 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2025 | 250 | 0.050 |
Why?
|
| Fiber Optic Technology | 1 | 2003 | 42 | 0.050 |
Why?
|
| Mediastinal Neoplasms | 1 | 2003 | 36 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2006 | 365 | 0.050 |
Why?
|
| Walking | 2 | 2020 | 226 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 204 | 0.050 |
Why?
|
| Hemiplegia | 1 | 2023 | 40 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2012 | 1546 | 0.050 |
Why?
|
| Muscle Strength | 1 | 2022 | 76 | 0.050 |
Why?
|
| Time and Motion Studies | 1 | 2021 | 16 | 0.040 |
Why?
|
| Depression | 2 | 2012 | 1308 | 0.040 |
Why?
|
| Heart Conduction System | 2 | 2000 | 163 | 0.040 |
Why?
|
| Diet | 1 | 2007 | 1097 | 0.040 |
Why?
|
| Patient Selection | 1 | 2005 | 722 | 0.040 |
Why?
|
| Mass Screening | 1 | 2006 | 812 | 0.040 |
Why?
|
| Postural Balance | 1 | 2021 | 134 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 448 | 0.040 |
Why?
|
| Malondialdehyde | 1 | 2020 | 48 | 0.040 |
Why?
|
| Syndrome | 1 | 2023 | 1157 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2004 | 472 | 0.040 |
Why?
|
| Partial Pressure | 1 | 2019 | 27 | 0.040 |
Why?
|
| Ventricular Fibrillation | 1 | 2000 | 51 | 0.040 |
Why?
|
| Verapamil | 1 | 1999 | 43 | 0.040 |
Why?
|
| Sympathetic Nervous System | 1 | 1999 | 50 | 0.040 |
Why?
|
| Emergency Nursing | 1 | 2019 | 8 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 1999 | 107 | 0.040 |
Why?
|
| Adolescent | 3 | 2013 | 20802 | 0.040 |
Why?
|
| Exercise Test | 2 | 2011 | 239 | 0.040 |
Why?
|
| Coronary Artery Bypass | 1 | 2022 | 513 | 0.040 |
Why?
|
| Young Adult | 1 | 2013 | 9987 | 0.040 |
Why?
|
| Registries | 1 | 2025 | 1610 | 0.030 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2019 | 85 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2005 | 1282 | 0.030 |
Why?
|
| Wrist | 1 | 2017 | 28 | 0.030 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1999 | 230 | 0.030 |
Why?
|
| Posture | 1 | 2017 | 135 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 229 | 0.030 |
Why?
|
| Bradycardia | 1 | 1996 | 57 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 723 | 0.030 |
Why?
|
| Oxygen | 1 | 2019 | 549 | 0.030 |
Why?
|
| Inflammation | 1 | 2023 | 1481 | 0.030 |
Why?
|
| Heart | 1 | 1999 | 659 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2014 | 270 | 0.030 |
Why?
|
| Prognosis | 2 | 2014 | 4848 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 423 | 0.030 |
Why?
|
| Dogs | 3 | 2000 | 616 | 0.020 |
Why?
|
| Reference Values | 1 | 2014 | 674 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2013 | 227 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2003 | 1218 | 0.020 |
Why?
|
| Radiography | 1 | 2014 | 740 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2015 | 347 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 234 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 151 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2012 | 272 | 0.020 |
Why?
|
| Telephone | 1 | 2012 | 110 | 0.020 |
Why?
|
| Viral Load | 1 | 2013 | 411 | 0.020 |
Why?
|
| Prednisone | 1 | 2012 | 237 | 0.020 |
Why?
|
| Education | 1 | 2012 | 112 | 0.020 |
Why?
|
| Albuterol, Ipratropium Drug Combination | 1 | 2011 | 2 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 1337 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 1212 | 0.020 |
Why?
|
| Self Care | 1 | 2012 | 230 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2010 | 317 | 0.020 |
Why?
|
| Salmeterol Xinafoate | 1 | 2008 | 12 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2012 | 1278 | 0.020 |
Why?
|
| Powders | 1 | 2008 | 24 | 0.020 |
Why?
|
| Research Design | 1 | 2012 | 711 | 0.020 |
Why?
|
| Health Services | 1 | 2007 | 69 | 0.020 |
Why?
|
| Psychotherapy, Group | 1 | 2007 | 58 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 747 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2007 | 178 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2007 | 107 | 0.020 |
Why?
|
| Immunity | 1 | 2007 | 179 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 1166 | 0.010 |
Why?
|
| Mucins | 1 | 2006 | 71 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2007 | 304 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 965 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2006 | 347 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2006 | 330 | 0.010 |
Why?
|
| Hospitals, Veterans | 1 | 2007 | 335 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2007 | 1481 | 0.010 |
Why?
|
| Macrophages | 1 | 2007 | 660 | 0.010 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2007 | 432 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2006 | 953 | 0.010 |
Why?
|
| Electrocardiography | 2 | 2000 | 972 | 0.010 |
Why?
|
| Cell Line | 1 | 2007 | 2554 | 0.010 |
Why?
|
| Epilepsy | 1 | 2009 | 864 | 0.010 |
Why?
|
| Cognition Disorders | 1 | 2006 | 552 | 0.010 |
Why?
|
| Biological Availability | 1 | 2002 | 136 | 0.010 |
Why?
|
| Gene Expression | 1 | 2006 | 1481 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 2577 | 0.010 |
Why?
|
| Catecholamines | 1 | 1999 | 50 | 0.010 |
Why?
|
| Norepinephrine | 1 | 1999 | 148 | 0.010 |
Why?
|
| Electrophysiology | 1 | 1999 | 243 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2000 | 242 | 0.010 |
Why?
|
| Epinephrine | 1 | 1999 | 148 | 0.010 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2000 | 216 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1999 | 533 | 0.010 |
Why?
|
| Refractory Period, Electrophysiological | 1 | 1996 | 8 | 0.010 |
Why?
|
| Cardiac Complexes, Premature | 1 | 1996 | 5 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 2000 | 758 | 0.010 |
Why?
|
| Mice | 1 | 2007 | 18172 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 2000 | 4646 | 0.000 |
Why?
|